Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice

British Journal of Nutrition

Volumn 108, Issue 12, 2012, Pages 2166-2175

  Cho, Su Jung ^a   Jung, Un Ju ^a   Choi, Myung Sook ^a  

^a Kyungpook National University   (South Korea)

Author keywords

Adiposity; Hepatic steatosis; High fat diet; Lipid regulating enzymes; Resveratrol

Indexed keywords

CHOLESTEROL; FAT DROPLET; FATTY ACID; FATTY ACID SYNTHASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; LIPID; PHOSPHATIDATE PHOSPHATASE; RESVERATROL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME INHIBITION; EPIDIDYMIS FAT; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY LIVER; FOOD INTAKE; INTRAABDOMINAL FAT; LIPID DIET; LIPID LIVER LEVEL; MALE; MOUSE; NONHUMAN; OBESITY; PROTECTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADIPOSITY; ANIMALS; CHOLESTEROL; DIET; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; FATTY LIVER; GLUCOSEPHOSPHATE DEHYDROGENASE; HYPERLIPIDEMIAS; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; PHOSPHATIDATE PHOSPHATASE; STILBENES; TRIGLYCERIDES; WEIGHT GAIN;

MUS;

EID: 84865150391     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114512000347     Document Type: Article

References (60)

1. Haslam DW & James WPT (2005) Obesity. Lancet 366, 1197-1209. (Pubitemid 41393598)
2. Thomas EL, Hamilton G, Patel N, et al. (2005) Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spec-troscopy study. Gut 54, 122-127. (Pubitemid 40007230)
3. Kuriyama H, Yamashita S, Shimomura I, et al. (1998) Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. Hepatology 27, 557-562. (Pubitemid 28081073)
4. Walker CG, Zariwala MG, Holness MJ, et al. (2007) Diet, obesity and diabetes: a current update. Clin Sci 112, 93-111. (Pubitemid 46120089)
5. Astrup A, Dyerberg J, Selleck M, et al. (2008) Nutrition transition and its relationship to the development of obesity and related chronic diseases. Obes Rev 1, 48-52. (Pubitemid 351643190)
6. Rastmanesh R (2011) High polyphenol, low probiotic diet for weight loss because of intestinal microbiota interaction. Chem Biol Interact 189, 1-8.
7. Hung LM, Chen JK, Huang SS, et al. (2000) Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 47, 549-555.
8. El-Mowafy AM & Alkhalaf M (2003) Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcino-genesis 24, 869-873. (Pubitemid 36748902)
9. de la Lastra CA & Villegas I (2007) Resveratrol as an antiox-idant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 35, 1156-1160. (Pubitemid 350206449)
10. Bowers JL, Tyulmenkov VV, Jernigan SC, et al. (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141, 3657-3667.
11. Hsu CL & Yen GC (2006) Induction of cell apoptosis in 3T3-L1 pre-adipocytes by flavonoids is associated with their antioxidant activity. Mol Nutr Food Res 50, 1072-1079.
12. Shang J, Chen LL, Xiao FX, et al. (2008) Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 29, 698-706. (Pubitemid 351799479)
13. Fischer-Posovszky P, Kukulus V, Tews D, et al. (2010) Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr 92, 5-15.
14. Szkudelska K, Nogowski L & Szkudelski T (2009) Resvera-trol, a naturally occurring diphenolic compound, affects lipo-genesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol 113, 17-24.
15. Lagouge M, Argmann C, Grhart-Hines Z, et al. (2006) Resver-atrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1a. Cell 127, 1-14.
16. Kim S, Jin Y, Choi Y, et al. (2011) Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol 81, 1343-1351.
17. Shang J, Chen LL & Xiao FX (2008) Resveratrol improves high-fat induced nonalcoholic fatty liver in rats. Zhonghua Gan Zang Bing Za Zhi 16, 616-619.
18. Rivera L, Morón R, Zarzuelo A, et al. (2009) Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 77, 1053-1106.
19. Tauriainen E, Luostarinen M, Martonen E, et al. (2011) Distinct effects of calorie restriction and resveratrol on diet-induced obesity and fatty liver formation. J Nutr Metab 525094 (epublication 1 October 2011).
20. Baur JA, Pearson KJ, Price NL, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342. (Pubitemid 44764104)
21. West DB, Boozer CN, Moody DL, et al. (1992) Dietary obesity in nine inbred mouse strains. Am J Physiol 262, R1025-R1032.
22. Ghibaudi L, Cook J, Farley C, et al. (2002) Fat intake affects adiposity, comorbidity factors, and energy metabolism of Sprague-Dawley rats. Obes Res 10, 956-963. (Pubitemid 135688910)
23. McGowan MW, Artiss JD, Strandbergh DR, et al. (1983) A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 29, 538-542. (Pubitemid 13160770)
24. Allain CC, Poon LS, Chan CS, et al. (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20, 470-475.
25. Folch J, Lees M & Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226, 497-509.
26. Hulcher FH & Oleson WH (1973) Simplified spectrophoto-metric assay for microsomal 3-hydroxy-3-methylglutaryl CoA reductase by measurement of coenzyme A. J Lipid Res 14, 625-631.
27. Carl MN, Lakshmanan MR & Porter JW (1975) FAS from rat liver. Methods Enzymol 35, 37-44.
28. Pitkänen E, Pitkänen O & Uotila L (1997) Enzymatic determination of unbound D-mannose in serum. Eur J Clin Chem Clin Biochem 35, 761-766. (Pubitemid 27478235)
29. Walton PA & Possmayer F (1985) Mg2-dependent phosphati-date phosphohydrolase of rat lung: development of an assay employing a defined chemical substrate which reflects the phosphohydrolase activity measured using membrane-bound substrate. Anal Biochem 151, 479-486. (Pubitemid 16160867)
30. Lazarow PB (1981) Assay of peroxisomal beta-oxidation of fatty acids. Methods Enzymol 72, 315-319.
31. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
32. Wierzbicki M, Chabowski A, Zendzian-Piotrowska M, et al. (2009) Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding. Adv Med Sci 54, 59-65.
33. Oosterveer MH, van Dijk TH, Tietge UJ, et al. (2009) High fat feeding induces hepatic fatty acid elongation in mice. PLoS One 4, e6066.
34. Collins S, Martin TL, Surwit RS, et al. (2004) Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav 81, 243-248. (Pubitemid 38670090)
35. Macarulla MT, Alberdi G, Gómez S, et al. (2009) Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet. J Physiol Biochem 65, 369-376.
36. Nelson GJ, Kelley DS, Schmidt PC, et al. (1987) The influence of dietary fat on the lipogenic activity and fatty acid composition of rat white adipose tissue. Lipids 22, 338-344.
37. Rodríguez VM, Macarulla MT, Chávarri M, et al. (2001) Lipo-protein lipase and lipogenic enzyme activities in adipose tissue from rats fed different lipid sources. J Physiol Biochem 57, 245-254. (Pubitemid 34026349)
38. Jiang L, Wang Q, Yu Y, et al. (2009) Leptin contributes to the adaptive responses of mice to high-fat diet intake through suppressing the lipogenic pathway. PLoS One 4, e6884.
39. Kim S, Jin Y, Choi Y, et al. (2011) Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol 81, 1343-1351.
40. Rayalam S, Yang JY, Ambati S, et al. (2008) Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipo-cytes. Phytother Res 22, 1367-1371.
41. Lasa A, Schweiger M, Kotzbeck P, et al. (2011) Resveratrol regulates lipolysis via adipose triglyceride lipase. J Nutr Biochem (epublication ahead of print version 2 May 2011).
42. Duval C, Muller M & Kersten S (2007) PPARR and dyslipide-mia. Biochim Biophys Acta 1771, 961-971.
43. Martin PG, Guillou H, Lasserre F, et al. (2007) Novel aspects of PPARalpha-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study. Hepatol-ogy 45, 767-777. (Pubitemid 46450628)
44. Sato A, Kawano H, Notsu T, et al. (2010) Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes 59, 2495-2504.
45. Kim S, Sohn I, Ahn JI, et al. (2004) Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. Gene 340, 99-109. (Pubitemid 39360236)
46. Ajmo JM, Liang X, Rogers CQ, et al. (2008) Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 295, G833-G842.
47. Paigen B (1995) Genetics of responsiveness to high-fat and high-cholesterol diets in the mouse. Am J Clin Nutr 62, 458-62S.
48. Davidson MH (2009) Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol 32, 482-486.
49. Do GM, Kwon EY, Kim HJ, et al. (2008) Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 374, 55-59.
50. Zern TL, West KL & Fernandez ML (2003) Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. J Nutr 133, 2268-2272. (Pubitemid 36841552)
51. Suckling KE & Stange EF (1985) Role of acyl-CoA, cholesterol acyl-transferase in cellular cholesterol metabolism. J Lipid Res 26, 647-671. (Pubitemid 15248938)
52. Zhu L, Luo X & Zin Z (2008) Effect of resveratrol on serum and liver lipid profile and antioxidant activity in hyperlipide-mia rats. Asian-Aust J Anim Sci 21, 890-895. (Pubitemid 351762198)
53. Sbarra V, Ristorcelli E, Petit-Thévenin JL, et al. (2005) In vitro polyphenol effects on activity, expression and secretion of pancreatic bile salt-dependent lipase. Biochim Biophys Acta 1736, 67-76. (Pubitemid 41208261)
54. de la Lastra CA & Villegas I (2007) Resveratrol as an anti-oxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 35, 1156-1160. (Pubitemid 350206449)
55. Furukawa S, Fujita T, Shimabukuro M, et al. (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114, 1752-1761. (Pubitemid 40385531)
56. Qatanani M & Lazar MA (2007) Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 21, 1443-1455. (Pubitemid 46955717)
57. Martin KR & Appel CL (2010) Polyphenols as dietary supplements: a double-edged sword. Nutr Diet Suppl 2, 1-12.
58. Dudley J, Das S, Mukherjee S, et al. (2009) Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem 20, 443-452.
59. Das S, Fraga CG & Das DK (2006) Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NF kappaB. Free Radic Res 40, 1066-1075. (Pubitemid 44480547)
60. Wilson T, Knight TJ, Beitz DC, et al. (1996) Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci 59, 15-21.